Drug intelligence / Profile preview

Chromic chloride

Development stage: Approved
Modality: Small Molecules
Administration: Intravenous

Overview

Chromic chloride is a sterile, nonpyrogenic solution used as an additive to intravenous solutions for total parenteral nutrition (TPN). It provides chromium in the form of chromic chloride hexahydrate (CrCl3•6H2O), which is essential for proper glucose metabolism and utilization. The compound acts as a trace mineral supplement to prevent chromium deficiency in patients receiving long-term TPN. Its mechanism of action involves serving as a cofactor for insulin action and enhancing the effects of insulin on carbohydrate, protein, and lipid metabolism[1][2][5].

Brand names: Multitrace-4Multitrace4Multitrace 4Multitrace-5Multitrace5Multitrace 5
Other names: chromic chloridechromic chloride hexahydratetrichlorochromium

Beyond the preview

Go deeper on Chromic chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromic chloride.

Explore the full profile